Reviewing Uroplasty (UPI) & Smith & Nephew (SNN)

Uroplasty (NASDAQ: UPI) and Smith & Nephew (NYSE:SNN) are both medical devices & implants companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, profitability and analyst recommendations.

Dividends

Smith & Nephew pays an annual dividend of $0.61 per share and has a dividend yield of 1.7%. Uroplasty does not pay a dividend. Smith & Nephew pays out 31.1% of its earnings in the form of a dividend. Smith & Nephew has increased its dividend for 4 consecutive years.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Uroplasty and Smith & Nephew, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Uroplasty 0 0 0 0 N/A
Smith & Nephew 0 3 1 0 2.25

Smith & Nephew has a consensus target price of $42.00, suggesting a potential upside of 20.41%. Given Smith & Nephew’s higher probable upside, analysts clearly believe Smith & Nephew is more favorable than Uroplasty.

Profitability

This table compares Uroplasty and Smith & Nephew’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Uroplasty -31.58% -87.33% -60.82%
Smith & Nephew 13.87% 15.84% 8.74%

Insider & Institutional Ownership

6.6% of Smith & Nephew shares are owned by institutional investors. 1.0% of Smith & Nephew shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Uroplasty and Smith & Nephew’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Uroplasty N/A N/A N/A ($0.30) -4.07
Smith & Nephew $4.67 billion 3.27 $784.00 million $1.96 17.80

Smith & Nephew has higher revenue and earnings than Uroplasty. Uroplasty is trading at a lower price-to-earnings ratio than Smith & Nephew, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Uroplasty has a beta of -1.26, meaning that its stock price is 226% less volatile than the S&P 500. Comparatively, Smith & Nephew has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500.

Summary

Smith & Nephew beats Uroplasty on 12 of the 13 factors compared between the two stocks.

About Uroplasty

Cogentix Medical, Inc. (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover. The Company’s products include Urgent PC Neuromodulation System, Macroplastique Bulking Agent, Endoscopy Systems and EndoSheath Technology. The Company is also engaged in the commercialization of the Urgent PC Neuromodulation System, a device which delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). Its Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) due to intrinsic sphincter deficiency (ISD). The Company offers 5000 and 7000 series of endoscopes, which are video endoscopy systems.

About Smith & Nephew

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices. The Sports Medicine Joint Repair franchise offers surgeons a range of instruments, technologies and implants necessary to perform minimally invasive surgery of the joints, including the repair of soft tissue injuries and degenerative conditions of the knee, hip and shoulder. The AET franchise offers an array of minimally invasive surgery-enabling systems and devices. The Trauma & Extremities franchise supports healthcare professionals with solutions used by surgeons to stabilize severe fractures, correct bone deformities, treat arthritis and heal soft tissue complications.

Receive News & Ratings for Uroplasty Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uroplasty and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply